Cellular and molecular gastroenterology and hepatology · 2025
MFAP4 Deficiency Attenuates Liver Fibrosis by Regulating Hepatic Stellate Cell Fate Through Inhibition of the FAK/PI3K/NFκB Signaling Pathway.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Linxiang, Li Bimin, Zhang Yue, Nie Yuan, Zhang Wang, Chen Peng, Huang Chenkai, Zhu Xuan
Аннотация
BACKGROUND & AIMS: Liver fibrosis, driven by chronic injury, hinges on hepatic stellate cells (HSCs) activation. Microfibrillar-associated protein 4 (MFAP4), an extracellular matrix protein critical for elastic fiber assembly, is up-regulated in hepatic fibrosis, yet its mechanistic role remains unclear.
METHODS: Liver fibrosis was induced in wild-type and Mfpa4 knockout mice using CCl4 and TAA, whereas LX-2 cells were activated with transforming growth factor-β1. Bioinformatics analysis, histopathology, double immunofluorescence, flow cytometry, Transwell coculture systems, Western blot, and quantitative polymerase chain reaction were used to identify the primary intrahepatic cell types expressing MFAP4 and assess its effects on HSCs activation and apoptosis.
RESULTS: MFAP4 is up-regulated in cirrhotic livers and is actively expressed in HSCs. Single-cell RNA sequencing analysis and Transwell coculture experiments revealed that the profibrotic effects of MFAP4 were primarily mediated through HSCs rather than hepatocytes. Inhibition of MFAP4 significantly reduces the expression of fibrosis markers in HSCs, inhibits their proliferation and migration, whereas overexpression of MFAP4 results in the opposite effect, accompanied by enhanced apoptosis resistance. In mouse models, global knockout of Mfap4 significantly alleviates CCl4- and TAA-induced liver fibrosis. Mechanistic analysis reveals that MFAP4 binds to integrin αvβ3 on the HSCs membrane, activating the FAK/PI3K/NFκB signaling pathway, which promotes HSC activation and survival, ultimately exacerbating liver fibrosis. Moreover, MFAP4 mediates a self-sustaining feedback loop via integrin αvβ3, maintaining HSCs activation and further promoting fibrosis progression.
CONCLUSIONS: MFAP4 governs HSCs activation and apoptosis resistance via integrin αvβ3-dependent FAK/PI3K/NFκB signaling. Targeting MFAP4 mitigates fibrosis by altering HSCs fate.
METHODS: Liver fibrosis was induced in wild-type and Mfpa4 knockout mice using CCl4 and TAA, whereas LX-2 cells were activated with transforming growth factor-β1. Bioinformatics analysis, histopathology, double immunofluorescence, flow cytometry, Transwell coculture systems, Western blot, and quantitative polymerase chain reaction were used to identify the primary intrahepatic cell types expressing MFAP4 and assess its effects on HSCs activation and apoptosis.
RESULTS: MFAP4 is up-regulated in cirrhotic livers and is actively expressed in HSCs. Single-cell RNA sequencing analysis and Transwell coculture experiments revealed that the profibrotic effects of MFAP4 were primarily mediated through HSCs rather than hepatocytes. Inhibition of MFAP4 significantly reduces the expression of fibrosis markers in HSCs, inhibits their proliferation and migration, whereas overexpression of MFAP4 results in the opposite effect, accompanied by enhanced apoptosis resistance. In mouse models, global knockout of Mfap4 significantly alleviates CCl4- and TAA-induced liver fibrosis. Mechanistic analysis reveals that MFAP4 binds to integrin αvβ3 on the HSCs membrane, activating the FAK/PI3K/NFκB signaling pathway, which promotes HSC activation and survival, ultimately exacerbating liver fibrosis. Moreover, MFAP4 mediates a self-sustaining feedback loop via integrin αvβ3, maintaining HSCs activation and further promoting fibrosis progression.
CONCLUSIONS: MFAP4 governs HSCs activation and apoptosis resistance via integrin αvβ3-dependent FAK/PI3K/NFκB signaling. Targeting MFAP4 mitigates fibrosis by altering HSCs fate.